CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CRL - CIK 0001100682

Market cap$8.97 B

Rank#1006

SEC filings2,387

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. trades as CRL and has a market capitalization of $8.97 B, making it the #1006 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $4.02B, down 0.9% from the prior year and net income of -$144.34M. This page tracks CHARLES RIVER LABORATORIES INTERNATIONAL, INC. through 2,387 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$4.02BFY 2025

Net income (latest FY)-$144.34MFY 2025

Operating cash flow (latest FY)$737.65MFY 2025

Total assets (latest FY)$7.14BFY 2025

Net margin-3.6%latest FY

Financial performance

Over the last 9 fiscal years CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s revenue grew from $1.68B to $4.02B, a compound annual growth rate of 10.2%. Net profit margin compressed from 9.2% to -3.6% over the same period - every figure below comes from the company's audited annual filings.

CRL annual revenueView details

Key statistics

Market cap: $8.97 B
Share price (derived)market cap / shares outstanding: $186.29
EPS (diluted)FY 2025: $-2.91
Shares outstandingas of 2026-04-24: 0.05B
Total equityas of 2026-03-28: $2.94B
Return on equity: -4.9%
Cash & equivalentsas of 2026-03-28: $191.83M
Stock buybacksFY 2025: $360.67M

Latest filings

Filing	Type	Filed
Insider trade	4	2026-05-14
Insider trade	4	2026-05-12
Insider trade	4	2026-05-12
Insider trade	4	2026-05-12
Insider trade	4	2026-05-11
Insider trade	4	2026-05-11
Insider trade	4	2026-05-11
Insider trade	4	2026-05-11

Browse the full filing history (2,387 filings)

Recent press releases

Charles River Laboratories to Present at William Blair and Jefferies Conferences2026-06-01
Charles River Laboratories to Present at William Blair and Jefferies Conferences | Charles River Laboratories International, Inc.
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions2026-05-13
Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions | Charles River Laboratories International, Inc.
Histology artifact QC, identifying tears, folds, bubbles, chatter, and related artifacts, targeted for release in Q3 20262026-05-11
Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow | Charles River Laboratories International, Inc.
Charles River Laboratories Announces First-Quarter 2026 Results2026-05-07
Charles River Laboratories Announces First-Quarter 2026 Results | Charles River Laboratories International, Inc.
Charles River Launches Rat In Vitro Fertility Services Demonstrating Embryology Capabilities2026-04-30
Charles River Launches Rat In Vitro Fertility Services Demonstrating Embryology Capabilities | Charles River Laboratories International, Inc.

Similar companies

The largest companies sharing CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s SEC industry classification (services-commercial physical & biological research).

IQVIQVIA Holdings Inc.$30.40 B CRL vs IQV

INCYIncyte Corporation$21.23 B CRL vs INCY

MEDPMedpace Holdings, Inc.$13.30 B CRL vs MEDP

ICLRICON Public Limited Company$11.04 B CRL vs ICLR

ABSIAbsci Corporation$1.04 B CRL vs ABSI

Frequently asked questions

What is CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s market cap?

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) has a market capitalization of $8.97 B as of 2026-06-10, ranking #1006 among US-listed companies.

How much revenue does CHARLES RIVER LABORATORIES INTERNATIONAL, INC. make?

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported revenue of $4.02B for fiscal year 2025, a decrease of 0.9% year over year.

Is CHARLES RIVER LABORATORIES INTERNATIONAL, INC. profitable?

In its latest fiscal year CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported a net loss of $144.34M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.